Searchable abstracts of presentations at key conferences in endocrinology

ea0065oc6.1 | Reproductive Endocrinology and Biology | SFEBES2019

Effect of MVT-602, a potent kisspeptin receptor agonist, on LH levels in healthy pre-menopausal women undergoing a minimal controlled ovarian stimulation protocol

Abbara Ali , Duijkers Ingrid , Ezzati Max , Voors Christine , Romeijn Christel , Berman Lance , Fan Xiaolin , Migoya Elizabeth , Dhillo Waljit S

Background: Kisspeptin is an endogenous neuropeptide that regulates GnRH release from the hypothalamus. Kisspeptin-54 has been shown to effectively trigger oocyte maturation during in vitro fertilisation (IVF) treatment, but with markedly reduced rates of ovarian hyperstimulation syndrome (OHSS). The kisspeptin receptor agonist, MVT-602, has a longer half-life than native kisspeptin-54 (1.5–2.2 h vs. 0.5 h) and has potential for development as a novel trigger of oocyte ma...

ea0099p498 | Endocrine-Related Cancer | ECE2024

Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: interim results from a phase 2, randomized, parallel-group study

Chauhan Aman , Mohamed Amr , Usiskin Keith , Mui Cosina , Dillon Joseph , Fan Xiaolin , Shaheen Shagufta , Manuel O'Connor Juan , Singh Simron , Lagast Hjalmar , Krasner Alan

Background: Carcinoid syndrome (CS), the most common functional neuroendocrine tumor (NET) syndrome, is characterized by watery diarrhea or cutaneous flushing. While somatostatin receptor ligand (SRL) depot injections are mainstay treatments for CS, discomfort with injections and inadequate symptom relief at labeled doses are seen with many patients. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS...